

REMARKS

Applicants have amended the Title of the Specification to correct minor typographical errors.

The IDS is provided to mention two "A" references cited in the IPER that were not mentioned in the PTO-1449 that was filed upon entry of this application into the US National Phase. This RCE is filed to allow submission of the IDS and PTO-1449.

CONCLUSION

It is respectfully asserted that in view of the amendments and remarks made above, the case is now in condition for allowance. A Notice of Allowance is respectfully requested.

If any minor issues remain precluding such allowance, the Examiner is requested to contact Applicants' representative at the number below.

Respectfully submitted,

/James P. Riek/

James P. Riek
Attorney for Applicants
Registration No. 39,009

Date: 4-22-2009
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988